Dr. GPCR Summit 2021
Dr. GPCR Ecosystem - Dr. GPCR Summit - Dr. GPCR Summit 2021 - Partner SynAbs
Meet Dr. GPCR Summit Partner
SYnAbs' vision is to fill the gap in the marketplace for innovative monoclonal antibodies against poor immunogenic compounds and complex antigens.
In order to address the challenge of raising monoclonals targeting transmembrane proteins, SYnAbs has developed a set of proprietary technologies, combining :
specific adjuvant and variable immunization routes to benefit from natural in-vivo maturation while breaking immune tolerance in rat-LOU and mouse species,
modification of peptide residues involved in ligand interaction,
plasmid vector, allowing the expression of a high surface density of the target transmembrane protein for a combination of genetic and whole-cell autologous immunization.
The application of these technologies has led to the generation of BTI-322 anti-CD2 rat monoclonal (Siplizumab humanized IgG1 version of BTI-322), and numerous other functional antibodies (anti-GPCR, anti-CD20,…).
Our custom monoclonal antibody generation service is a one-stop solution, from antigen design to multi-gram manufacturing of the monoclonal of interest.